Navigation Links
InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
Date:11/6/2008

- Third quarter net loss narrows on higher revenue due to Roche milestone -

BRISBANE, Calif., Nov. 6 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced results from operations for the third quarter and nine months ended September 30, 2008. InterMune reported a net loss for the third quarter of 2008 of $12.5 million, or $0.32 per share, compared with a net loss of $23.1 million, or $0.66 per share, in the third quarter of 2007.

Dan Welch, Chairman, Chief Executive Officer and President of InterMune said, "Third quarter and recent events have highlighted our significant progress on pirfenidone and ITMN-191. On October 16, Shionogi's Japanese NDA for pirfenidone was approved, making pirfenidone the first drug approved for idiopathic pulmonary fibrosis (IPF) in any major market in the world. We reported exceptional patient retention in our Phase 3 CAPACITY program for pirfenidone in IPF and we set the expectation for announcement of top-line results from CAPACITY in January or February of 2009. With ITMN-191, we remain committed to announcing top-line results of our triple combination study of ITMN-191 with Pegasys(R) (pegylated interferon alfa-2a) and Copegus(R) (ribavirin) during this quarter."

Results for Third Quarter 2008

InterMune reported total revenue in the third quarter of 2008 of $23.3 million, compared with total revenue of $11.4 million in the third quarter of 2007. Total revenue in the third quarter of 2008 primarily consisted of revenue from the collaboration with Roche for the development of protease inhibitors, including ITMN-191 (R7227), which totaled $15.8 million in the third quarter of 2008, compared with $0.8 million in the same quarter of 2007. Third quarter 2008 collaborati
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... (PRWEB) October 24, 2014 The ... the nation’s leading nonprofit authority on the use ... information exchange, announces its appointment of four new ... The workgroup leaders include:, ,     Peter ...     Erik Pupo, Specialist Leader, Deloitte Consulting LLP ...
(Date:10/25/2014)... (PRWEB) October 24, 2014 SonaCare ... focused ultrasound (HIFU) technology, announced that its Board ... as Chief Executive Officer, President and member of ... Dr. Carol will take-on expanded responsibilities within the ... as well as overseeing commercialization, manufacturing and finance. ...
(Date:10/25/2014)... , October 24, 2014 ... clinical-stage pharmaceutical company focused on the development of oral ... Nadav Kidron will present at FireRock Capital,s ... Capital,s Annual Micro-Cap Conference ,Date: Tuesday, October 28, 2014 ... New York City , ...
(Date:10/25/2014)... -- Investor-Edge has initiated coverage on the ... Vertex Pharmaceuticals Inc. (NASDAQ: VRTX ), Alexion ... Inc. (NASDAQ: PPHM ), and StemCells Inc. ... be accessed at: http://investor-edge.com/register . The ... a positive note as the Dow Jones Industrial Average ...
Breaking Biology Technology:WEDI Appoints Four New Security and Privacy Workgroup Co-chairs 2SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 2SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 3Oramed to Present at the FireRock Annual Micro-Cap Conference 2Oramed to Present at the FireRock Annual Micro-Cap Conference 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 4Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 5
... for Combining Efficiency and Renewables into an Energy ... recognized as an important component to America' energy ... discussion about including Energy Efficiency into what many ... Standards (RPS) . The whole idea being that ...
... Merge eFilm announced Wednesday that its net income ... same quarter last year. Though its net sales, at ... bottom line suffered because it paid more than twice ... quarter ending June 30 were $1,497,000, up from $1,400,000 ...
... partnership to provide travel solution , ,ROCHESTER, ... Concur Technologies, Inc. announced Monday the formation ... that will deliver benchmarking information to travel managers ... Runzheimer, an international consulting firm specializing in travel ...
Cached Biology Technology:Energy efficiency is no longer the Rodney Dangerfield of energy 2Energy efficiency is no longer the Rodney Dangerfield of energy 3Runzheimer and Concur develop travel management service 2
(Date:10/15/2014)... from strains of influenza virus increases with the latest ... complacent that the most substantial threats have been identified, ... arise when a new virus strain – against which ... in the human population. There have been five such ... which – the 1918 Spanish Flu – cost 50 ...
(Date:10/15/2014)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ... growing mobile commerce market releases photos and video of the recent ... October 13 th . Gino Pereira , ... angel investor Mr. Chad A. Verdi rang the bell.  ... his investors and employees "for their work and dedication in bringing ...
(Date:10/14/2014)... of years since T. rex took its ... scientists is breathing life back into dinosaurs using high-powered ... research has important implications for how dinosaurs used their ... sense of smell and cool their brains. , ... student Jason Bourke, lead author of the new study ...
Breaking Biology News(10 mins):Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3
... -- Scientists from The Forsyth Institute and Kings College, ... community, the Human Oral Microbiome Database, which provides descriptions ... commonly found in peoples mouths. Most bacteria living ... maintaining the health of teeth and gums, as well ...
... a biosensing nanodevice developed by Arizona State University ... airport security checkpoints and revolutionize health screenings for ... aureus (MRSA). Even more incredible than the ... the worlds tiniest rotary motor: a biological engine ...
... ... covert data -, LAKE WORTH, Fla., March 24 ... produce the,world,s first self-authenticating passport. It was introduced in the new,Belgian passport ... produces the Belgian passport,has added an optical decoder page in the passport ...
Cached Biology News:Scientists launch human oral microbiome database 2Biosensing nanodevice to revolutionize health screenings 2Biosensing nanodevice to revolutionize health screenings 3FCO and GSSC Team to Create World's First Self-Authenticating Passport 2
... work in collaboration with Pall Life Sciences ... in a variety of membrane chemistries. The ... on the Caliper TPWII, MultiDose, Prelude, and ... our Automation Certified Syringe Filters are available ...
... The Mini-PROTEAN 3 Dodeca cell with multi-casting ... of up to 12 mini format handcast (8.3 ... cm) gels. The cell requires 3.4-4.4 L of ... cooling coil that attaches to an external refrigerated ...
...
... has been developed to significantly increase the ... Stability is increased at room temperature ... This product is subjected to 0.2 ... azide. This formulation insures consistently high ...
Biology Products: